Selicrelumab

N/A

Report date: 2024/11/07 20:00:06

Base Information

Drug NameSelicrelumab
Drug Alias NameRG-7876RO-7009789
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumoursLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoche Pharma AgF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksN/A